ORMP Oramed Pharmaceuticals Forecast, Technical & Fundamental Analysis
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins... Show more
ORMP is expected to report earnings to fall 89.67% to 18 cents per share on November 16
Q3'26
Est.
$0.19
Q2'26
Beat
by $1.69
Q4'25
Beat
by $0.08
Q3'25
Beat
by $0.19
Q2'25
Missed
by $0.03
The last earnings report on August 24 showed earnings per share of $1.84, beating the estimate of 15 cents. With 84.12K shares outstanding, the current market capitalization sits at 200.08M.
A.I. Advisor
published General Information
General Information
a company which engages in pharmaceutical preparations
A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with DRTS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then DRTS could also see price increases.
ORMP's Stochastic Oscillator is staying in overbought zone for 5 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ORMP broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 30, 2026. You may want to consider a long position or call options on ORMP as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ORMP just turned positive on August 03, 2026. Looking at past instances where ORMP's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
ORMP moved above its 50-day moving average on August 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ORMP crossed bullishly above the 50-day moving average on August 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ORMP advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 159 cases where ORMP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.630) is normal, around the industry mean (20.145). P/E Ratio (1.165) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). ORMP has a moderately high Dividend Yield (0.052) as compared to the industry average of (0.018). P/S Ratio (90.909) is also within normal values, averaging (444.692).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
